AP-305™ Antibody Drug Conjugates
Antibody-Drug Conjugates (ADCs) are a form of targeted immunotherapy composed of a monoclonal antibody attached, via a linker, to a chemotherapy ‘warhead’. Unlike chemotherapy, ADCs can target and kill cancer cells while sparing healthy cells.
AP-305TM: A unique monoclonal antibody recognizing membrane Hsp70 expressed on cancers (cmHsp70.1) which is conjugated to proprietary linker-drug constructs releases the drug when the ADC is internalized into tumors expressing membrane Hsp70.
AP-305TM: A unique monoclonal antibody recognizing membrane Hsp70 expressed on cancers (cmHsp70.1) which is conjugated to proprietary linker-drug constructs releases the drug when the ADC is internalized into tumors expressing membrane Hsp70.
